AUTL

Autolus TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.40

Analysis reference price unavailable

Analysis 2026-04-29 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$1.60

Analysis reference price unavailable

Analysis 2026-04-29 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$0.80

Analysis reference price unavailable

Analysis 2026-04-29 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-29

AI commentary

Primary evidence quality is decent for a low-coverage biotech because recent SEC filings are available, but forward visibility is still limited and most of the thesis remains a monitoring view around launch execution and binary data. AUTL was at $1.41 at 21:35 UTC on April 29, 2026, down 5.4% from the prior close on the day of the restructuring 8-K, which suggests the market treated the update cautiously even with guidance maintained. Analyst revision data are unavailable in the packet, so the post-filing read-through should be treated as tentative rather than a confirmed sentiment inflection.

RankAlpha Sentiment Codex - 2026-04-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystQ3 2026 completion of workforce reduction is the nearest execution checkHigh impact

Autolus said its board approved an operational-efficiency plan that eliminates about 13% of the workforce, inclusive of actions begun in 2H25, with roughly $8 million of total charges and completion expected by Q3 2026. Management also reaffirmed 2026 AUCATZYL net product revenue guidance, so the near-term test is whether spending falls without disrupting launch or development execution [#8-K-2026-04-29].

2026-12-31event2026 AUCATZYL revenue delivery remains the core operating catalystHigh impact

The 10-K reported $74.3 million of 2025 net product revenue, a U.K. launch under routine NHS commissioning, and no expected EU sales in 2026, while the April 29, 2026 8-K reaffirmed full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million. Hitting that guide would help validate launch scaling, but the revenue base is still concentrated in one product [#10-K-2026-03-27][#8-K-2026-04-29].

2026-12-31catalystEnd-2026 BOBCAT data is the clearest pipeline optionality eventHigh impact

Autolus disclosed that first patients were dosed in October 2025 in the BOBCAT Phase 1 dose-escalation study in progressive multiple sclerosis, with initial data expected at the end of 2026. A constructive readout could expand the obe-cel story beyond adult B-ALL, but this is still an early, binary biotech catalyst [#10-K-2026-03-27].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-29 • Updated nightlySource: Internal modelMethodology